http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112358515-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H17-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H17-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate | 2020-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112358515-B |
| titleOfInvention | Application of a naringenin (4-O-methyl) glucoside compound in the preparation of anti-inflammatory or lipid-lowering drugs |
| abstract | The invention discloses the application of a naringenin (4- O -methyl) glucoside compound in the preparation of anti-inflammatory or lipid-lowering drugs. 7 Production of certain inflammatory factors produced by macrophages, such as nitric oxide (NO); also shown to down-regulate or inhibit mouse 3T3‑L1 preadipocyte proliferation and significantly reduce lipid production during cell differentiation Number of droplets. Its effect is better than that of aglycone, and compared with aglycone, the water solubility of the compound is significantly enhanced; compared with glucoside, the compound has higher conversion efficiency and higher yield; compared with glucoside, the compound has less toxicity, It has wider application value. |
| priorityDate | 2020-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 129.